

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **Sinco Pharmaceuticals Holdings Limited**

### **兴科蓉医药控股有限公司**

*(Incorporated under the laws of the Cayman Islands with limited liability)*

**(Stock Code: 6833)**

## **COMPLETION OF SUBSCRIPTION OF NEW SHARES UNDER GENERAL MANDATE**

References are made to the announcements issued by Sinco Pharmaceuticals Holdings Limited (the “**Company**”) dated 23 July 2021 and 27 July 2021 (the “**Announcements**”) in relation to, among other things, the Subscription. Unless otherwise defined, capitalised terms used in this announcement shall have the same meanings as those defined in the Announcements.

### **COMPLETION OF THE SUBSCRIPTION**

The Board is pleased to announce that as of the date of this announcement, all conditions under the Subscription Agreements have been fulfilled and the Completion took place on 28 September 2021 in accordance with the terms and conditions of the Subscription Agreements. An aggregate of 169,000,000 Subscription Shares have been allotted and issued to the Subscribers at the Subscription Price of HK0.5 per Subscription Share.

## EFFECTS ON SHAREHOLDING STRUCTURE OF THE COMPANY

Set out below are the shareholding structure of the Company immediately before and after the Completion:

Name of Shareholder	Immediately before the Completion		Immediately after the Completion	
	Number of Shares	Approximate (%)	Number of Shares	Approximate (%)
Risun Investments Limited <sup>(Note 1)</sup>	1,050,000,000	62.06	1,050,000,000	56.42
The Subscribers	–	–	169,000,000	9.08
Other public Shareholders	641,890,585	37.94	641,890,585	34.50
<b>Total</b>	<b>1,691,890,585</b>	<b>100.00</b>	<b>1,860,890,585</b>	<b>100.00</b>

*Note:*

- Mr. Huang Xiangbin is the settlor of a trust in which Wickhams Cay Trust Company Limited is the trustee and holds the entire interest in Fullwealth Holdings Limited, which in turn holds the entire beneficial interest in Risun Investments Limited. Fullwealth Holdings Limited, Wickhams Cay Trust Company Limited and Mr. Huang Xiangbin are deemed to be interested in the 1,050,000,000 Shares beneficially held by Risun Investments Limited.

By order of the Board  
**Sinco Pharmaceuticals Holdings Limited**  
**Huang Xiangbin**  
*Chairman and Executive Director*

Sichuan, the PRC, 28 September 2021

*As at the date of this announcement, the executive Director is Mr. Huang Xiangbin; and the independent non-executive Directors are Mr. Lau Ying Kit, Mr. Wang Qing, Mr. Liu Wenfang and Mr. Bai Zhizhong.*